Dr. Zhiyuan Zhong
Distinguished Professor
Dean of International College of Pharmaceutical Innovation
Dean of College of Pharmaceutical Sciences
Associate Editor of Journal of Controlled Release (IF 10.8)
E-mail：zyzhong@suda.edu.cn
Biography
Zhiyuan Zhong is a Distinguished Professor and Dean of International College of Pharmaceutical Innovation and College of Pharmaceutical Sciences of Soochow University, and Associate Editor of Journal of Controlled Release (IF 10.8). His research focuses on controlled drug delivery systems, targeted cancer therapy, and cancer immunotherapy. He has co-authored 320 papers with over 25000 times of citation (H-Index 83). He is a Highly Cited Researcher by Clarivate Analytics as from 2018. He was a Vice President of Suzhou BioBAY (a leading Biomedical Park in China), and an Associate Editor of Biomacromolecules (ACS). He is on the Editorial/Advisory Board of eight international journals including Materials Today, Biomacromolecules, ACS Biomaterials Science & Engineering, Materials Today Chemistry, and PLoS One. He received several awards, including Distinguished Young Scholar Award from the National Natural Science Foundation of China (2012), the Bessel Research Award from the Alexander von Humboldt Foundation (2013), Award for Breakthrough Technologies in Drug Delivery Systems in Asia from the Japanese Society of Drug Delivery System (2013), and Biomacromolecules/Macromolecules Young Investigator Award from the American Chemical Society (ACS, 2014). He is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
Select Publications (* represents corresponding author)
1. S.J. Yue, J.N. An, Y.F. Zhang, J.Y. Li, C.Z. Zhao, J.Y. Liu, L.L. Liang, H.L. Sun*, Y. Xu*, Z.Y. Zhong*, Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukemia, Adv. Mater. 2023, 2209984.
2. J.W. Du, S.J. Yue, C.M. Li, J.Y. Li, S.S. Zhao, Y.Y. Dong, Y.F. Zhang, R. Cheng, H.L. Sun*, Z.Y. Zhong*, Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia, Nano Today 2023, 50, 101872.
3. W.C. Yan, B.B. Guo, Z. Wang a, J.T. Yang, Z.Y. Zhong*, F.H. Meng*, RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors, J. Control. Release 2023, 360, 304-315.
4. Y.J. Li, X.Y. Li, J.M. Yi, Y.J. Cao, Z.H. Qin*, Z.Y. Zhong*, W.J. Yang*, Nanoparticle-Mediated STING Activation for Cancer Immunotherapy, Adv. Healthc. Mater. 2023, 2300260
5. M.Y. He, M.Y. Wang, T. Xu, M.Y. Zhang, H.X. Dai, C. Wang*, D.W. Ding*, Z.Y. Zhong*, Reactive oxygen species-powered cancer immunotherapy: Current status and challenges, J. Control. Release 2023, 356, 623-648.
6. J.G. Xie, X.F. Zhao, P. Zhang, Y.Y. Zhang, R. Cheng, Z.Y. Zhong*, C. Deng*, Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia, Adv. Sci. 2023, 10, 2204866.
7. B.B. Guo, Y. Qu, Y.P. Sun, S.S. Zhao, J.D. Yuan, P.Z. Zhang, Z.Y. Zhong*, F.H. Meng*, Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative cold triple-negative breast cancer, Bioactive Mater. 2023, 25, 61-72.
8. Y.P Sun, Y.J.Sha, G.H. Cui, F.H. Meng*, Z.Y. Zhong*, Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy, Adv. Drug Deliv. Rev. 2023, 192, 114624.
9. Y.F. Xia, J.N. An, J.Y. Li, W.X. Gu, Y.F. Zhang, S.S. Zhao, C.Z. Zhao, Y. Xu, B. Li, Z.Y. Zhong*, F.H. Meng*, Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia, Bioactive Mater. 2023, 21, 499-510.
10. J. Sun, Z.Y. Huangfu, J.T. Yang, G.L. Wang*, K. Hu*, M.Y. Gao, Z.Y. Zhong*, Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation, Adv. Drug Deliv. Rev. 2022, 190, 114538.
11. X.Y.Ji*, Z.Y. Zhong*, External stimuli-responsive gasotransmitter prodrugs: Chemistry and spatiotemporal release, J. Control. Release 2022, 351, 81-101.
12. J.J. Jiang, R.X. Wang, L. Yang, Y.J. Sha, S.S. Zhao, D.F. Chen*, Z.Y. Zhong*, F.H. Meng*, IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma, J. Control. Release 2022, 350, 460-470.
13. J.Y. Liu, L. Zhang, D.X. Zhao, S.J. Yue, H.L. Sun*, C.F. Ni*, Z.Y. Zhong*, Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy, J. Control. Release 2022, 350, 122-131.
14. H. Zheng, B.B. Guo, X.Y. Qiu, Y.F. Xia, Y. Qu, L. Cheng*, F.H. Meng*, Z.Y. Zhong*, Polymersome-Mediated Cytosolic Delivery of Cyclic Dinucleotide STING Agonist Enhances Tumor Immunotherapy, Bioactive Mater. 2022, 16, 1-11.
15. Y. Zheng*, Z.Y. Zhong*, Roadmap to next-generation cancer vaccines, J. Control. Release 2022, 347, 308-313.
16. J.J. Wei, D. Wu, Y. Shao, B.B. Guo, J.J. Jiang, J. Chen, J.P. Zhang, F.H. Meng*, Z.Y. Zhong*, ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy, J. Control. Release 2022, 347, 68-77.
17. J.J. Wei, D. Wu, S.S. Zhao, Y. Shao, Y.F. Xia, F.H. Meng*, D.W. Ni, X.Y. Qiu, J.P. Zhang, J. Chen*, and Z.Y. Zhong*, Immunotherapy of Malignant Glioma by Non-Invasive Administration of TLR9 Agonist CpG Nano-immunoadjuvant, Adv. Sci. 2022, 9, 2103689.
18. H.H. Fang, Y.J. Sha, L. Yang, J.J. Jiang, L.C. Yin, J.Y. Li, B. Li, B. Klumperman, Z.Y. Zhong*, and F.H. Meng*, Macrophage-Targeted Hydroxychloroquine Nanotherapeutics for Rheumatoid Arthritis Therapy, ACS Appl. Mater. Interfaces 2022, 14, 8824-8837.
19. X.Y.Qiu, Y.Qu, B.B.Guo, H.Zheng, F.H. Meng*, and Z.Y. Zhong*, Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer, J. Control. Release 2022, 341, 498-510.
20. Y.F. Zhang, S.J. Yue, H.L. Sun*, R. Haag, Z.Y. Zhong*, An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer, J. Control. Release 2021, 340, 331-341.
21. Z. Wang, F.H. Meng, and Z.Y. Zhong*, Emerging targeted drug delivery strategies toward ovarian cancer, Adv. Drug Deliv. Rev. 2021, 178, 113969
22. N. Yu, Y.F. Zhang, J.Y. Li, W.X. Gu, S.J. Yue, B. Li, F.H. Meng, H.L. Sun*, R. Haag, J.D. Yuan, and Z.Y. Zhong*, Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma, Adv. Mater. 2021, 33, 2007787.
23. Y.H. Wei, Y.P. Sun, J.J. Wei, X.Y. Qiu, F.H. Meng*, G. Storm*, J.D. Yuan, Z.Y. Zhong*, Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo, J. Control. Release 2021, 337, 521-529.
24. W.X. Gu, R.B. Qu, F.H. Meng*,J.L.M. Cornelissen*, and Z.Y. Zhong*, Polymeric Nanomedicines Targeting Hematological Malignancies, J. Control. Release 2021, 337, 571-588.
25. Y.F. Xia, J.J. Wei, S.S. Zhao, B.B. Guo, F.H. Meng*, B. Klumperman, and Z.Y. Zhong*, Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma, J. Control. Release 2021, 336, 262-273.
26. Q.Y. Fan, Y.Y. Liu, G.H. Cui, Z.Y. Zhong*, and C. Deng*, Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma, J. Control. Release 2021, 329, 1139-1149.
27. W.X. Gu, T.H. Liu, D.Y. Fan, J.B. Zhang, Y.F. Xia, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, Z.J. Liu, and Z.Y. Zhong*, A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia, J. Control. Release 2021, 329, 706-716.
28. W.X. Gu, F.H. Meng*, R. Haag, and Z.Y. Zhong*, Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation, J. Control. Release 2021, 329, 676-695.
29. C. Gao, Q. Cheng, J.W. Wei, C. Sun, S.Y. Lu, C.H.T. Kwong, S.M.Y. Lee, Z.Y. Zhong*, and R.B. Wang*, Bioorthogonal supramolecular cell-conjugation for targeted hitchhiking drug delivery, Mater. Today 2020, 40, 9-17.
30. C. Deng*, Q. Zhang, J.Q. Guo, X.F. Zhao, and Z.Y. Zhong*, Robust and smart polypeptide-based nanomedicines for targeted tumor therapy, Adv. Drug Deliv. Rev. 2020, 160, 199-211.
31. Y.H. Wei, F.H. Meng*, G. Storm, and Z.Y. Zhong*, Transferrin-Binding Peptide Functionalized Polymersomes Mediate Targeted Doxorubicin Delivery to Colorectal Cancer In Vivo, J. Control. Release 2020, 319, 407-415.
32. Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J. van Hest, and Z.Y. Zhong*, CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma in Mice, J. Control. Release 2020, 320, 421-430.
